TMDA/DMC/MRE/F/016 Rev #:02

TMDA

THEUNITEDREPUBLICOFTANZANIA



MINISTRY OF HEALTH

TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY

PUBLIC ASSESSMENT REPORT FOR GABICA[™] 150 MG (PREGABALIN 150 MG) HARD GELATIN CAPSULES

Version number 01, 03/01/2023

TMDA Headquarters, Plot No. 56/1, Block E, Kisasa B Centre, Swaswa Road, P. O. Box 1253, Dodoma – Tanzania, Telephone: +255 (26) 2961989/2061990/+255 (22) 2450512/2450751/2452108, Email: info@tmda.og.tz, Website: www.tmda.go.tz

Toll free: 0800110084

1. Introduction

GabicaTM 150 mg is a generic medicine of Lyrica 150 mg hard capsules of Pfizer Limited, is an analogue of the neurotransmitter gamma-aminobutyric acid (GABA). Pregabalin decreases central neuronal excitability by binding to an auxiliary subunit (α 2- δ protein) of a voltage-gated calcium channel on neurons in the central nervous system. Pregabalin reduces the release of several neurotransmitters, including glutamate, noradrenaline, and substance. GabicaTM 150 mg is approved in Tanzania for use only in adult patients.

1.1 Product details

Registration number	TAN 21 HM 0300		
Brand name	Gabica [™] 150 mg		
Generic name, strength, and	Each hard gelatin capsule contains 150 mg		
form	Pregabalin		
ATC classification	ATC Code- N03AX16 (Anti-epileptics, other		
	antiepileptics)		
Distribution category	РОМ		
Country of origin	Pakistan		
Associated product	Gabica [™] 50 mg and Gabica [™] 75 mg		
Marketing Authorization Holder	Getz Pharma (Pvt) Limited		
	29-30/27, Korangi Industrial Area, Karachi-74900		
	Pakistan		
Local Technical	Planet Pharmaceuticals Limited		
Representative	P. O. Box 38328,		
	Dar es Salaam		

1.2 Assessment procedure

The application for registration of GabicaTM 150 mg was submitted on 23/07/2020. The product underwent full assessment. Assessment was completed in 3 (three) rounds of evaluation and the product was registered on 20/08/2021.

1.3 Information for users

Visual description of the finished product	Hard gelatin capsule with dark blue opaque cap and yellow opaque body printed Getz logo and 150mg in black containing which powder
Primary packing material	Aluminium – Aluminium Blister
Secondary packing materials	A printed carton box
Shelf-life and storage condition	24 months, Do not store above 30°C
	Protect from sunlight and moisture
Route of administration	Oral

Therapeutic indications	- Neuropathic pain Pregabalin is indicated for the treatment of peripheral and central neuropathic pain in adults.
	 Epilepsy Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised Anxiety Disorder Pregabalin is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults Postherpetic neuralgia. Pregabalin is indicated for the treatment of Postherpetic neuralgia Fibromyalgia syndrome (FMS) Pregabalin is indicated for the treatment of Fibromyalgia syndrome (FMS)

2. Labelling and product information

Summary of product characteristics

The SmPC included all the relevant information to ensure correct and safe use of the medicine by healthcare providers. The complete SmPC can be accessed <u>here</u>.

Package insert/leaflet

The package insert is confirmed to be derived from the SmPC and contains sufficient data for the end user. Since the product is POM, the package insert contains full prescribing information as per SmPC.

Container labels

The product label information is presented in English. Details in the secondary pack label include:

Brand name: Gabica[™] 150 mg

Composition: Each Hard gelatin capsule contains 150 mg Pregabalin

Pack size: 35 capsules

Manufacturing details: batch number, manufacturing date, and expiry date

Storage conditions: Do not store above 30°C. Protect from sunlight and moisture

Manufacturer address: physical address of release site

Unique identifier: Not applicable

Special warnings/precautions or instructions for use: See enclosed leaflet. The product contains lactose

The details of the primary pack include:

Brand name and strength: Gabica[™] 150 mg (Each hard gelatin capsule contains 150 mg Pregabalin)

Manufacturing details: batch number, and expiry date

Name of manufacturer: Getz Pharma (Pvt) Limited

The content of the primary and secondary labels was aligned to the requirements of the Part V of the Compendium: Guidelines on Format and Content of Product Labels for Medicinal products. The label contains sufficient information for proper identification of the medicine and post marketing follow up of the product.

Mock labels are appended as annex I.

3. Scientific discussion

Quality of Active Pharmaceutical Ingredients

Information on the quality of the API was submitted in form of DMF.


General Information

Pregabalin API is compendia in USP, Ph.Eur. and BP.

Molecular formula: C₈H₁₇NO₂

Chemical name: (3S)-3-(Aminomethyl)-5-methylhexanoic acid

Structure:



General properties

Pregabalin is a white or almost white powder, sparingly soluble in water, slightly soluble in methanol in $25\pm2^{\circ}$ C, very slightly soluble in isopropyl alcohol, freely soluble in 1 mol/L HCL and 1 mol/L NaOH solution, soluble in 0.1 mol/L HCL and 0.1 mol/L NaOH

solution, sparingly soluble in isopropyl alcohol and water (1:1 w/w) The drug substance exhibits polymorphism. Form A is manufactured. The drug substance shows isomerism. The drug substance corresponds to the S-enantiomer. A test for the enantiomeric purity is included in the drug substance specification.

Pregabalin drug substance falls into the category of BCS class I, being a highly soluble and highly permeable compound, therefore polymorphism and PSD are not critical parameters for performance of this drug product.

Manufacture

Pregabalin API manufacturer is Aurisco Pharmaceuticals Co. Limited, Badu Industrial Park Zone, Tiantai, Zhejiang Province 317200, P.R China. The manufacturing complies with GMP requirements as evidenced by the GMP certificate issued by the Freie und Hansestadt Hamburg. Pregabalin API is manufactured by chemical synthesis using conventional techniques. Sufficient controls of quality of materials and in-process checks were employed throughout the manufacturing process.

Specifications

The API specifications were set as per Ph.Eur. standards and ICHQ3A. The parameters monitored during quality control are: Appearance (visual inspection), solubility, identity (IR and HPLC), assay (HPLC), related impurities (HPLC), sulfated ash, bulk density, and tapped density. Compliance to these specifications were established via batch analysis data and stability studies.

Stability and container closure system

The re-test period of Pregabalin API is 36 months when packed in the original container with storage condition 'Store at temperature below 25°C'.

Quality of the Finished Pharmaceutical Product

Formulation

Gabica[™] 150 mg is a hard gelatin capsule with pink opaque cap and yellow opaque body printed Getz logo and 150mg in black containing white powder.

Gabica[™] 150 mg contains the Pregabalin and other ingredients listed here after: Lactose Monohydrate, Pregelatinized Starch, Purified Talc, Empty Gelatin Capsule Size # 2 (FD&C Red 3, FD&C Yellow 5, FD&C Blue 1, FD&C Yellow 6, Titanium Dioxide, Gelatin). The quantities of all ingredients are confirmed to be in line with the recommendations of Handbook of Pharmaceutical Excipients, 8th Edition in terms of function and quantities. Ingredient, Lactose is of safety concern therefore appropriate warnings were included in the product label.

Manufacture

The finished product manufacturer is Getz Pharma (Pvt) Limited, 29-30/27, Korangi Industrial Area, Karachi-74900, Pakistan. The compliance of the site to TMDA GMP standards was confirmed through desk-review on 21/06/2021.

Specifications

The FPP is compendia in BP. The manufacturer controls the quality of the finished product as per in-house standards and ICH requirements. The parameters monitored during quality control are: appearance (visual inspection), identification (HPLC, IR), disintegration, average weight, dissolution, uniformity of dosage unit by weight variation, assay (HPLC), impurities (HPLC), loss on drying, microbial content. Compliance to the standard was established using batch analysis data and stability data.

Stability and container closure system

Stability studies were conducted on 3 (three) batches of the finished product stored at $30 \pm 2^{\circ}$ C & RH: 75 $\pm 5^{\circ}$ RH for 24months and $40 \pm 2^{\circ}$ C & RH: 75% $\pm 5^{\circ}$ RH for 6 months. Based on the stability data presented, the approved shelf-life is 24 months when stored in Aluminum-Aluminium blisters with storage condition 'Do not store above 30° C. Protect from sunlight and moisture'.

Safety and efficacy information

The biowaiver was approved based on BCS classification.

GabicaTM 150 mg fulfilled the criteria for waiving an in-vivo bioequivalence study as per relevant TMDA guidance. Dissolution profiles of GabicaTM 150 mg was compared to Lyrica capsule 150 mg. At least 85% of the labelled amount of Pregabalin had dissolved in all three media. Therefore, confirming similarity.

4. Benefit-Risk Assessment and Conclusion

On basis of the data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. GabicaTM 150 mg is recommended for registration.

5. Benefit-Risk Assessment and Conclusion

On basis of the data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. GabicaTM 150 mg is recommended for registration.

6. Post-approval updates

Variation applications

Reference number	Date submitted	Change requested	Recommendation	Granting date

Feedback from pharmacovigilance, post marketing surveillance and enforcement activities

Type of feedback	Impact	Response

Re-registration applications

Application for renewal of registration was submitted on <DDMMYYYY>. The application was finalized in <number> rounds of evaluation. The product was confirmed to still be compliant to the standards of quality, safety and efficacy, hence registration was renewed on <DDMMYYY>.

PART 5: CHANGE HISTORY

Version number	Date	Description of update	Section(s) Modified	Approval date

Annex I: Mock up label

Primary label:

